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Abstract
Background: Angiocidin plays a key role in angiogenesis and tumor progression. High angiocidin expression is detected in
some kind of solid tumors and tumor vascular endothelial cells. Several reports have shown the inhibition of angiogenesis
and tumor growth caused by angiocidin. However, the role of angiocidin in liver cancers growth is still unclear.
Objectives: To examine angiocidin expression in SMMC-7221 and HepG2 cells and the role of  angiocidin in liver cancer cell
growth.
Methods: RT-PCR and western blot are used in this study to detect angiocidin expression. SiRNA and MTT experiments
are used in exploring the role of angiocidin in tumor cell growth.
Results: Our study showed high angiocidin expression in two kinds of liver cancer cells. Angiocidin protein production in
HepG2 cells were reduced significantly by siRNA. When HepG2 cells were transfected with siRNA-angiocidin, these cells
showed very low proliferation activity compared with control cells. Our study suggests that reduction of  angiocidin may
contribute to decreased proliferation activity in liver cancer cells.
Conclusion: Angiocidin is highly expressed in liver cancer cells, and it may play a key role in tumor growth of liver cancers.
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Hepatocellular carcinoma (HCC) is one of the most
common cancers in the world. Patients with low-
grade HCC tumors often undergo unnoticed in many
years, and they always have a poor prognosis when
the tumors develop to high-grade. Many genes are
involved in the development and growth of HCC,
some may work cooperatively in promoting tumor
growth1,2. Looking for new genes involved in tumor
growth may help to uncover the mechanism in HCC
development.
Angiocidin was first cloned in 1993 from lung
tumor extracts as a tumor cell receptor for CSVTCG,
which is a thrombospondin adhesive domain. The
amino acid sequence of angiocidin only has three
additional amino acids at positions 769–771
compared with anti-secretory factor (ASF) and S5a3.
Angiocidin proteins are detected in many kinds of
tumor tissues such as breast carcinoma, head and
neck carcinoma, and colon carcinoma4,5. Interestingly,
high expression of angiocidin are detected in the
tumor epithelium, while very low expression in
surrounding normal tissues epitheliums6. In the serum
of HCC patients, angiocidin protein production
elevated accompanied by tumor progression7, which
suggests that angiocidin may be a new gene target
for therapy of  tumors. Several reports have shown
that angiocidin are involved in invasion and
angiogenesis of  tumors. In human umbilical vein
endothelial (HUVE) cells, cell proliferation and
migration decreased remarkably when angiocidin
expressions were inhibited. The similar result was
got in colon cancer cells. Colon cancer cells expressing
low- level angiocidin exhibited very low proliferation
rates than high expression cells. In vivo, nude mice
injected with low angiocidin expression colon cancer
cells develop significantly smaller tumors than the
mice injected with normal cells8-12. These above results
suggest that angiocidin may play a key role in tumor
growth. However, the role of angiocidin in tumor
growth (especially liver cancer) remains largely
unknown.
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In this study, angiocidin expression and its role
in liver cancer cells were examined. Both SMMC-
7221 and HepG2 cells showed high angiocidin
protein expression. To indicate the role of  angiocidin
in liver cancer growth, siRNA-angiocidin were
designed and used in inhibiting angiocidin protein
production. HepG2 cells transfected with siRNA-
angiocidin showed slower growth compared with
control cells. Our study suggests that reduction of
angiocidin contributes to the low proliferation activity
of  HepG2 cells.
Methods
Cell culture
SMMC-7221 and HepG2 cells were grown in
Dulbecco’s modified Eagle medium (DMEM,
Sigma) containing 10% fetal bovine serum, 100 U/
ml penicillin, 100 ug/ml streptomycin. Monolayer
cells were maintained at 37oC and 5% CO2. When
cells grow nearly 60% confluency, they are passaged.
Lipofectamine 2000 (Invitrogen) was used to
introduce the plasmids into cells.
Construction of siRNA target to angiocidin
Two specific siRNA sequences against angiocidin
were designed by siRNA Target Finder (Ambion).
The sense sequence of siRNA1 is 5’-
aacaacgtgggccttatcaca-3’, and sense sequence of
siRNA2 is 5’-aagatgcgcatcattgccttt-3’, which were
constructed into pSilencer 4.1 CMV-neo vectors. A
nonsilencing siRNA was used as negative control.
All the constructs were verified by DNA sequencing.
RNA isolation and RT-PCR
Total RNA was isolated from cells using the Trizol
reagent according to the manufacturer’s instructions.
The prepared RNA was then reversely transcribed
to single-stranded cDNAs using oligo(dT) primers
(Invitrogen). The cDNA was as the template in
polymerase chain reaction (PCR) using angiocidin
specific primers. The angiocidin primers are: 5’
aagatggtgttggaaagcac 3’, 5’ tcacttcttgtcttcctccttc 3’.
Beta-actin expression was a negative control in the
process of PCR.
MTT assay
After two days of transfection, HepG2 cells (4000/
well) were seeded onto a 96-well plate and incubated
at 37°C. Three days later, 20 ul MTT (5 mg/ml in
PBS) solution added to each well, and the plate was
then incubated at 37°C for a further 4 hours. The
medium and MTT were removed from the wells
and the crystals dissolved in 150ul of  DMSO. After
10 min of shaking, the absorbance was measured at
490 nm (OD490) using a microplate reader.
Immunofluorescence
Cells were seeded on glass cover slips for 12 h and
then transfected with each indicated constructs.
Twenty-four hours after transfection, the cells were
fixed with 4% paraformaldehyde in PBS for 15 min,
then washed with PBS and permeabilized with 0.1%
Triton X-100 in PBS for 10 min. The cells were
blocked by incubation in PBS containing 2% BSA
(Sigma-Aldrich) for 1h at room temperature. The
cells were then exposed to a polyclonal rabbit anti-
rat angiocidin antibody (1:200) overnight at 4oC. After
washing, a Cy3-conjugated sheep anti-rabbit IgG
secondary antibody (1:500, Sigma-Aldrich) was
applied for 30 min at room temperature. The cells
were washed with PBS and photographed by an
OLYMPUS IX71 microscope.
Western Blot
After 72h of transfection,  total protein were
extracted with lysis buffer (150 mM NaCl, 20 mM
Tris, 5 mM EDTA pH7.5, 1% Triton X-100, and
supplemented with 1mM PMSF). BCA Protein
Assay Reagent kit (Pierce) was used to determine
the protein concentration. Equal amounts of protein
(10ug) were separated by SDS-PAGE and
transferred to PVDF membranes. The membranes
were blocked in TBST buffer containing 5% non-
fat milk for 1 h, and incubated with angiocidin
antibody (1:500) for 2 h at room temperature. After
three times of washing with TBST buffer, PVDF
membranes were then incubated with goat anti-
rabbit IgG horseradish peroxidase conjugated
(1:5000) for 1 h at room temperature. Three times
of washing are needed, and incubation with the
ECL reagent (Amersham), chemiluminescence signals
were detected on X-ray film and quantitated by
image analysis.
Results
Angiocidin expressed in SMMC-7221 and
HepG2 cells.
The angiocidin expression in two kinds of liver cancer
cells are examined by RT-PCR and western blot.
Fig.1a shows that angiocidin proteins are detected in
SMMC-7221 and HepG2 cells. There seems to be
not significant differences in angiocidin expression
between SMMC-7221 and HepG2 cells. Moreover,
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angiocidin mRNA and protein in HepG2 cells are
studied through RT-PCR and immunoflurence
technology. As can been seen from Figures 1b and
Figure 1: The angiocidin expression in liver cancer cells.
A: Western blot analysis of  angiocidin protein expression in SMMC-7221 and HepG2 cells.
B: The angiocidin mRNA expression in HepG2 cell indicated by RT-PCR analysis.
C: Immunofluorescence analysis showing the angiocidin expression in HepG2 cells
siRNA-angiocidin inhibited angiocidin
expression in HepG2 cells.
In order to study the role of angiocidin in tumor
growth, siRNA- angiocidin were designed and
constructed. siRNA-control, siRNA-angio1 and
siRNA-angio2 were introduced into HepG2 cells
according to the instruction of Lipofectamine 2000.
The angiocidin protein production was detected
through western blot analysis after 72 h of
transfection. Figure 2 showed that the angiocidin
protein productions were reduced by 60% via
siRNA-angio1, while angiocidin protein in untreated
and control cells unchanged. However, angiocidin
protein production in cells transfected siRNA-angio2
seems not be influenced compared with control. The
unchanged Beta-actin expression in all groups
suggested that angiocidin expression was specifically
inhibited by siRNA. Our results demonstrated that
siRNA-angio1 can remarkably inhibit angiocidin
expression in HepG2 cells while siRNA-angio2 does
not work in gene silencing.
1c, we got the conclusion that angiocidin expressed
in HepG2 cells.
Figure 2: Angiocidin expression was reduced by siRNA-angio in HepG2 cells.
(A) Western blot analysis showing the angiocidin reduction in HepG2 cells.
(B) Quantification of angiocidin protein reduction as in A. Error bars represent standard deviation
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Reduction of angiocidin inhibited the HepG2
cells proliferation.
To examine the role of  angiocidin in tumor cell
growth, MTT assay was performed using the
siRNA-angio1 treated HepG2 cells. Figure 3 showed
that cell proliferation in transfected siRNA-angio1
HepG2 cells is much lower than that untreated cells.
And siRNA-control has no effect on cell
proliferation. These results mean that reduced
angiocidin may be associated with slow growth of
HepG2 cells.
Figure 3: siRNA-angio inhibits cell proliferation
activity of HepG2 cells. Error bars represent
standard deviation
Discussion
Accumulating evidence have shown angiocidin
expressed in many solid and tumors tumor cell lines
such as breast carcinoma, head and neck carcinoma,
and colon carcinoma. Over-expressed angiocidin
detected in sarcomas and human colon cancer
specimens suggests angiocidin expression has a
positive correlation with tumor grade. The similar
phenomenon was found in hepatocellular carcinoma
patients with high angiocidin expression, in contrast
to the nearly undetectable levels in healthy persons7.
Our study also showed that in vitro high angiocidin
expressions were detected in two kinds of liver
cancer cells, SMMC-7221 and HepG2 cells. These
results suggested that angiocidin may contribute to
the tumor growth, and it may be a potential gene
target for tumor therapy.
Inhibiting angiocidin expression in colon cancer
cells and in breast cancer cells have been reported
by several groups recently13,14. In this study, we
indicated for the first time the angiocidin expression
in liver cancer cells. Using siRNA, endogenously
expressed angiocidin was inhibited significantly in
HepG2 cells. The angiocidin protein productions
were inhibited significantly via siRNA-angio1.
However, siRNA-angio2 does not work in inhibiting
angiocidin production. The failure of siRNA-angio2
in angiocidin inhibiting may be attributed to off-target
effects or other reasons. Our study showed that
reduced angiocidin protein may be involved in low
cell proliferation of  HepG2 cells, suggesting a key
role of angiocidin in liver cancer cell growth.
Recently, advances have been made in study role
of angiocidin in tumor growth. Godek J and his
colleagues revealed a possible pathway how
angiocidin works in tumor cell growth. He suggested
by activating epidermal growth factor receptor and
nuclear factor kappa (NF-8B), angiocidin can inhibit
cell growth in breast cancer cells15. Yang X et al
reported that under the regulation of angiocidin
matrix metalloproteinase 2 (MMP-2) and gelatinolytic
activity contribute to the invasive activity of HUVE
cells. It is therefore likely that the study of  angiocidin
in tumor growth will be an area of intensive
investigation in the near future. Further studies are
needed to uncover the mechanism.
Conclusion
In this study, we showed that angicidin protein
express highly in two kinds of liver cancer cells, and
reduction of angiocidin may contribute to decreased
proliferation ability of  liver cancer cells.
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